摘要
目的观察紫杉醇联合顺铂二线治疗难治型小细胞肺癌(SCLC)的疗效及毒副反应。方法 29例难治型SCLC患者分为治疗组(22例)和对照组(7例)。治疗组给予紫杉醇135 mg·m-2,第1天;顺铂25mg·m-2,第1～3天,每21 d为1周期,2周期化疗后疗效和毒副反应被评价。对照组给予最佳支持治疗。治疗后2组患者生存情况被评价。结果治疗组22例患者化疗有效率为31.82%,中位总生存时间为6.6个月,毒副反应可耐受;对照组7例患者中位生存时间为4.5个月。结论紫杉醇联合顺铂二线治疗难治型SCLC疗效肯定,毒副反应轻。
Objective To investigate the efficiency and toxicities of taxol combined with cisplatin as the secondline chemotherapy in the treatment of patients with refractory small cell lung cancer （SCLC）. Methods Twentynine patients with refractory SCLC were divided into two groups. The 22 patients in the treatment group received the chemotherapy： taxol 135 mg. m-2, d1 ; cisplatin 25 mg . m-2, d1-3, every 21 days was 1 cycle, the efficacy and toxicities were evaluated after 2 cycles of chemotherapy. The other 7 patients in the control group received the best supportive care. The overall survival was observed in the two groups. Results In the treatment group, the response rate was 31.82%, the median overall survival was 6.6 months, the toxicities were tolerated. In the control group, the median overall survival was 4.5 months. Conclusion Taxol combined with cisplatin as the second-line chemotherapy is effective in the treatment of patients with refractory SCLC, and the toxicities are mild.
出处
《肿瘤基础与临床》
2012年第3期211-213,共3页
journal of basic and clinical oncology
关键词
紫杉醇
难治型小细胞肺癌
二线化疗
taxol
refractory small cell lung cancer
second-line chemotherapy
